Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

被引：0

作者：

Wang, Tingyu ^{[1
]}

Sun, Xiuhua ^{[2
]}

Qiu, Lihua ^{[3
]}

Su, Hang ^{[4
]}

Cao, Junning ^{[5
]}

Li, Zhiming ^{[6
]}

Song, Yuqin ^{[7
]}

Zhang, Li ^{[8
]}

Li, Dengju ^{[9
]}

Wu, Huijing ^{[10
]}

Zhang, Wei ^{[11
]}

Li, Junmin ^{[12
]}

Zhou, Keshu ^{[13
]}

Zhou, Hui ^{[14
]}

Yang, Yu ^{[15
]}

Li, Zhifeng ^{[16
,17
]}

Cen, Hong ^{[18
]}

Cai, Zhen ^{[19
]}

Zhang, Zhihui ^{[20
]}

Fu, Weijun ^{[21
]}

Jie, Jin ^{[22
]}

Li, Fei ^{[23
]}

Wu, Weixin ^{[24
]}

Gu, Xuekui ^{[25
]}

Zhu, Weiliang ^{[26
]}

Liu, Lihong ^{[27
]}

Li, Zengjun ^{[1
]}

Yi, Shuhua ^{[28
]}

Bao, Hanying ^{[29
]}

Xu, Zusheng ^{[29
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Bloo, Tianjin, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[4] Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China

[5] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] State Key Lab Oncol South China, Guangzhou, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China

[10] Hubei Canc Hosp, Wuhan, Peoples R China

[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Beijing, Peoples R China

[12] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[13] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[14] Cent South Univ, Xiangya Sch Med, Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China

[15] Fujian Med Univ, Tumor Hosp, Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China

[18] Guangxi Med Univ, Tumor Hosp, Nanning, Peoples R China

[19] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[20] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China

[21] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Shanghai, Peoples R China

[22] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[23] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[24] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China

[25] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[26] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China

[27] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[28] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[29] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177820

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
Fowler, Nathan H.
Dickinson, Michael
Dreyling, Martin
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason P.
Ghosh, Monalisa
Popplewell, Leslie L.
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, Joy
Perez-Simon, Jose Antonio
Nagle, Sarah J.
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres J. M.
Teshima, Takanori
Patten, Piers
McGuirk, Joseph P.
Petzer, Andreas
Offner, Fritz C.
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Pacaud, Lida Bubuteishvili
Forcina, Alessandra
Zia, Aiesha
Schuster, Stephen J.
Thieblemont, Catherine
BLOOD, 2020, 136
[42] Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Jacobson, Caron A.
Chavez, Julio C.
Sehgal, Alison R.
William, Basem M.
Munoz, Javier
Salles, Gilles
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Yakoub-Agha, Ibrahim
Oluwole, Olalekan O.
Fung, Henry Chi Hang
Rosenblatt, Joseph
Rossi, John M.
Goyal, Lovely
Plaks, Vicki
Yang, Yin
Vezan, Remus
Avanzi, Mauro P.
Neelapu, Sattva S.
LANCET ONCOLOGY, 2022, 23 (01): : 91 - 103
[43] Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 13 - 14
[44] Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
O'Connor, Owen A.
Lue, Jennifer K.
Sawas, Ahmed
Amengual, Jennifer E.
Deng, Changchun
Kalac, Matko
Falchi, Lorenzo
Marchi, Enrica
Turenne, Ithamar
Lichtenstein, Renee
Rojas, Celeste
Francescone, Mark
Schwartz, Lawrence
Cheng, Bin
Savage, Kerry J.
Villa, Diego
Crump, Michael
Prica, Anca
Kukreti, Vishal
Cremers, Serge
Connors, Joseph M.
Kurvuilla, John
LANCET ONCOLOGY, 2018, 19 (02): : 257 - 266
[45] Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
[46] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Jerkeman, Mats
Eskelund, Christian Winther
Hutchings, Martin
Raty, Riikka
Wader, Karin Fahl
Laurell, Anna
Toldbod, Helle
Pedersen, Lone Bredo
Niemann, Carsten Utoft
Dahl, Christina
Kuitunen, Hanne
Geisler, Christian H.
Gronbaek, Kirsten
Kolstad, Arne
LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
[47] Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, Anas
Oki, Yasuhiro
Bociek, R. Gregory
Kuruvilla, John
Fanale, Michelle
Neelapu, Sattva
Copeland, Amanda
Buglio, Daniela
Galal, Ahmed
Besterman, Jeffrey
Li, Zuomei
Drouin, Michel
Patterson, Tracy
Ward, M. Renee
Paulus, Jessica K.
Ji, Yuan
Medeiros, L. Jeffrey
Martell, Robert E.
LANCET ONCOLOGY, 2011, 12 (13): : 1222 - 1228
[48] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Chau, Quincy
Ramchandren, Radhakrishnan
BLOOD, 2012, 120 (21)
[49] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
Johnston, P. B.
Ansell, S. M.
Colgan, J. P.
Habermann, T. M.
Inwards, D. J.
Markovic, S. N.
Micallef, I. N.
Porrata, L. F.
LaPlant, B. R.
Geyer, S. M.
Witzig, T. E.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[50] Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Salles, Gilles
Schuster, Stephen J.
de Vos, Sven
Wagner-Johnston, Nina D.
Viardot, Andreas
Blum, Kristie A.
Flowers, Christopher R.
Jurczak, Wojciech J.
Flinn, Ian W.
Kahl, Brad S.
Martin, Peter
Kim, Yeonhee
Shreay, Sanatan
Will, Matthias
Sorensen, Bess
Breuleux, Madlaina
Zinzani, Pier Luigi
Gopal, Ajay K.
HAEMATOLOGICA, 2017, 102 (04) : E156 - E159

← 1 2 3 4 5 →